| Literature DB >> 26999191 |
Abstract
Transdermal drug delivery offers several advantages, including avoidance of erratic absorption, absence of gastric irritation, painlessness, noninvasiveness, as well as improvement in patient compliance. With this mode of drug administration, there is no pre-systemic metabolism and it is possible to increase drug bioavailability and half-life. However, only a few molecules can be delivered across the skin in therapeutic quantities. This is because of the hindrance provided by the stratum corneum. Several techniques have been developed and used over the last few decades for transdermal drug delivery enhancement. These include sonophoresis, iontophoresis, microneedles, and electroporation. Electroporation, which refers to the temporary perturbation of the skin following the application of high voltage electric pulses, has been used to increase transcutaneous flux values by several research groups. In this review, transdermal electroporation is discussed and the use of the technique for percutaneous transport of low and high molecular weight compounds described. This review also examines our current knowledge regarding the mechanisms of electroporation and safety concerns arising from the use of this transdermal drug delivery technique. Safety considerations are especially important because electroporation utilizes high voltage pulses which may have deleterious effects in some cases.Entities:
Keywords: diffusion; drug delivery; electroporation; pulse; transdermal
Year: 2016 PMID: 26999191 PMCID: PMC4810085 DOI: 10.3390/pharmaceutics8010009
Source DB: PubMed Journal: Pharmaceutics ISSN: 1999-4923 Impact factor: 6.321
Figure 1Schematic representation of local transport region (LTR) and local dissipation region (LDR).
Figure 2Experimental setup for transdermal electroporation.
Electroporation-mediated transdermal delivery of selected compounds across different skin models.
| Year and Reference | Electroporation Method | Molecular Species | Skin Model |
|---|---|---|---|
| 2013, [ | 70 to 570 V electric pulses | doxorubicin, fentanyl, FITC-labelled dextran | mouse skin |
| 1994, [ | 100–300 V | metoprolol | hairless rat skin |
| 2000, [ | 88 ± 25 V | terazosin hydrochloride | hairless rats |
| 2010, [ | 120 V | doxepin | porcine skin |
| 2003, [ | 300 V | nalbuphine | rat skin |
| 2000, [ | 130 V | tetracaine | rat skin |
| 2013, [ | 45 and 500 V | calcein | porcine skin |
| 1995, [ | 150–350 V | heparin | human skin |
| 2003, [ | 150–600 V | benzoic acid | hairless rat skin |
| 2003, [ | 400 V | timolol | human skin |
| 2003, [ | 500 V | mannitol | hairless rat |